This content is from: Patents

Managing IP survey: SPC framework

Managing IP is seeking views from in-house counsel at pharma and biotech companies on the state of the SPC framework in Europe; including Article 3a, the waiver and unitary SPCs

biotech200You can take the survey here

Please only take the survey if you are an in-house lawyer from a pharmaceutical, biotech or life sciences company.

We are looking to gain and share insight on how in-house IP counsel view the SPC framework in Europe; including Article 3a, the SPC Manufacturing Waiver and unitary SPCs. 
This is the second in our series of in-house surveys in 2019. You can read the special report on the findings of that survey, on the changing dynamic between artificial intelligence and IP, here.
Don’t miss the chance to have your say.
The survey should take no longer than five minutes to complete, and all responses will only be published in an aggregated and anonymised form. The more responses we get, the more illuminating the final report will be.
If you would like to discuss your thoughts in more detail, please contact Patrick Wingrove at

The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.

© 2021 Euromoney Institutional Investor PLC. For help please see our FAQs.


Instant access to all of our content. Membership Options | 30 Day Trial